京东大药房携手泽德曼启动专项行动 特惠关爱特应性皮炎患者

Core Insights - The collaboration between Zedman Pharmaceuticals and JD Health aims to provide affordable access to innovative treatments for patients with atopic dermatitis through a promotional campaign during JD's 11.11 shopping festival [1][2] - Zedman’s product, Zeli Mei cream, is the first aromatic receptor innovation drug approved for treating eczema in children over 2 years old and adults, demonstrating a high efficacy rate of 83.9% in clinical trials for children aged 7-11 [1] - The partnership emphasizes a comprehensive health management system that includes prevention, diagnosis, and treatment, enhancing JD Health's supply chain capabilities in dermatological products [1] Summary by Sections Collaboration Details - Zedman Pharmaceuticals and JD Health launched a "Caring for Patients" initiative, allowing patients to purchase Zeli Mei cream for only 10 yuan after receiving a 350 yuan coupon [1] - This initiative is part of a broader strategy to ensure patients have access to innovative treatment options through compliant drug supply channels [1] Product Information - Zeli Mei cream is a non-hormonal treatment for eczema, recognized for its safety and effectiveness, with mild to moderate adverse reactions reported [1] - The product has achieved a dual breakthrough in providing rapid itch relief and long-term skin repair [1] Previous Initiatives - In September, JD Health and Zedman initiated the "Health Escort, Safe Transition" campaign to support seasonal health issues, further expanding their collaboration in the dermatological sector [1] - The partnership leverages JD Health's full-chain capabilities in medical services, testing, diagnosis, and medication [1] Safety and Compliance - Zedman Pharmaceuticals values JD Health's strict identity verification, prescription review, and drug traceability systems, which ensure patient safety and respect for drug distribution regulations [2]